Methods of An Open-Label Proof-Of-Concept Trial of Intravenous Valproic Acid for Severe COVID-19
Full Title: Methods of An Open-Label Proof-Of-Concept Trial of Intravenous Valproic Acid for Severe COVID-19

Cover Title: A Trial of Intravenous Valproic Acid for Severe COVID-19

Authors: Erwin Chiquete\textsuperscript{a}, Liz Toapanta-Yanchapaxi\textsuperscript{a}, Carlos Cantú-Brito\textsuperscript{a}

\textsuperscript{a} Neurology and Psychiatry Department. Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”. Mexico City, Mexico.

Number of tables: 0

Number figures: 1

Number of figures: 1

Characters count in title: 96

Abstract word count: 254

Text word count: 1680

Number of references: 25
Methods of An Open-Label Proof-Of-Concept Trial of Intravenous Valproic Acid for Severe COVID-19

Erwin Chiquete¹, Liz Toapanta-Yanchapaxi¹, Carlos Cantú-Brito¹

¹ Neurology and Psychiatry Department. Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”. Mexico City, Mexico.
**Corresponding authors:**

Dr. Erwin Chiquete. Departamento de Neurología y Psiquiatría. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Avenida Vasco de Quiroga No.15, Colonia Belisario Domínguez Sección XVI, Delegación Tlalpan C.P.14080. Ciudad de México. México. E-mail: erwinchiquete@hotmail.com. Tel: +52 5424 7200 ext. 4177.

**Competing conflicts of interest / Disclosures:**

The authors have no relevant conflicts of interest to declare.

**Source of funding:**

The Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and CONACyT will sponsor this proof-of-concept interventional study. A larger clinical trial, in case of success of this pilot study, will have several sources of sponsorship.
[ABSTRACT]

Introduction: Coronavirus disease 2019 (COVID-19) is the systemic entity caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause death through severe atypical pneumonia and acute lung injury. Valproic acid (VPA) has shown anti-inflammatory activity and mild intrinsic antiviral effect. These properties warrant the study of VPA as a possible active treatment in persons with severe COVID-19.

Methods: Consecutive adult patients needing invasive mechanical ventilation (IMV) will be given intravenous (i.v.) VPA at a starting dose of 20 mg/kg/day and up to 60/kg/day (in 60 min i.v. infusions in 250 mL normal saline) as needed to reach plasma VPA concentrations of 50-100 µg/mL (measured every 72 h). These patients will be followed-up for 10 days for the primary outcome and for a further period of 30 days after treatment completion for the secondary outcome of recurrence. The primary study outcome is the reduction in the case fatality rate of at least 50% after 10 days of treatment (as compared with natural history). Secondary outcomes are the reduction of length of stay (LOS) of at least 50%, as well as COVID-19 recurrence at 30-day follow-up. The most important safety outcomes are acute liver failure, acute pancreatitis, and thrombocytopenia.

Conclusion: Although long-term adverse effects and even pro-inflammatory consequences have been reported with the chronic use of VPA, given the urgent need for a drug against COVID-19 to shorten the high mortality and LOS, the study of VPA is justified from a scientific standpoint.

Keywords: Atypical pneumonia, coronavirus, COVID-19, Mexico, pandemics, valproate, valproic acid.
Introduction

Coronavirus disease 2019 (COVID-19) is the systemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause death through severe atypical pneumonia and acute lung injury. There is a need for useful molecules that may cut the rate of deaths and hospital length of stay (LOS) that produce such a high sanitary burden. Given the urgent need for high-efficacy drugs, repurposed molecules may be the most efficient approach given the scarce time to limit the sanitary and economic impact of the present pandemics.

Valproic acid (VPA, the conjugate base is valproate) is available as sodium, semi sodium, and magnesium. VPA is a drug primarily used to treat epilepsy, bipolar disorder, as well as migraine. Chemicaly VPA is a weak organic acid that was first synthesized in 1882 as an analog of valeric acid, found naturally in the plant valeriana officinalis. VPA was tested initially as a solvent of organic compounds, and latter found serendipitously to be active in animals and humans as an anticonvulsant in 1962. It is a carboxylic acid clear liquid at room temperature. VPA was first approved in France (1967) for use in humans as an anti-epileptic medication.

VPA attenuates the expression of pro-inflammatory cytokines in preclinical models and in humans especially during the acute treatment phase, although conflicting results have been reported. This molecule has also shown intrinsic antiviral activity probably due to its activity as histone deacetylase inhibitor. VPA has shown anti-inflammatory activity in myocardial as well as neural tissue in models of brain and spinal cord injuries, although with some conflicting findings.

Although long-term adverse effects and even pro-inflammatory consequences have been reported with the chronic use of VPA, we believe that, given the urgent need to have
a useful drug to shorten the high mortality and LOS associated with COVID-19,\textsuperscript{21,22} the study of the safety and efficacy of VPA in the treatment of COVID-19 is warranted from a scientific standpoint.

**Methods**

**Study type**

Open-label proof-of-concept interventional study.

**Hypothesis**

Intravenous valproic acid will be safe and effective in the treatment of patients with severe COVID-19.

**Intervention**

Sodium valproic acid will be given intravenously at a starting dose of 20 mg/kg/day and up to 60/kg/day as needed to reach plasma valproic acid concentration of 50-100 µg/mL (measured every 72 h). Three equal doses per day given intravenously in infusions lasting 60 min in 250 mL normal saline.

**Study oversight and ethical considerations**
Ten days of i.v. treatment for the primary outcome, plus 30 days for the secondary outcome of COVID-19 recurrence, given a total of 40 days of follow-up.

Population

Patients admitted with severe COVID-19 to the ICU of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ).

Main study outcomes

Primary outcomes:

• Reduction in a case fatality rate (CFR) of at least 50%, from a known proportion of 40% to 20% after 10 days of treatment.

Secondary exploratory outcomes:

• Reduction of length of stay (LOS) of at least 50%, from a known median LOS of 10 days to 5 days after at least 5 days of i.v. valproic acid exposition.

• No COVID-19 recurrence during a 30-day observational period, after completion of the 10-day i.v. therapy.

Selection criteria

Inclusion criteria:
• Patients aged >18 years
• Both sexes
• Positive to SARS-CoV-2 RNA in nasopharyngeal samples by RT-PCR
• Severe acute respiratory syndrome treated with IMV at study recruitment
• Any time elapsed since symptoms onset to study recruitment
• Any length of hospital stay
• Any length of IMV
• Signed informed consent from patient or legal proxy
• No known VPA allergy
• Patients with or without previous or current exposure to anti-epileptics
• Patients with or without previous or current exposure to chloroquine, hydroxychloroquine or azithromycin
• Patients not participating in an interventional trial
• Patients not under current valproate treatment
• Patients not under current treatment with remdesivir
• Patients not under current treatment with tocilizumab

Exclusion criteria:

• Decline of informed consent
• Signs of VPA allergy
• Any acute severe side effect (either thrombocytopenia, acute liver disease, moderate-to-severe hypertransaminasemia, or acute pancreatic injury)
• Incomplete information for primary outcome *

*Intention-to-treat analysis (ITT) will be performed, considering study dropouts as failures.
**Recruitment strategy**

Consecutive patients needing IMV and meeting selection criteria will be given i.v. valproic acid for 10 days maintaining a plasma concentration of 50-100 µg/mL (measured every 72 h). These patients will be followed-up for 10 days for the primary outcome and for a further period of 30 days after treatment completion.

**Safety outcomes**

The most important acute side effects of valproic acid that should be meticulously on a daily basis examined are:

- **Acute liver failure**, defined as the severe acute liver injury with encephalopathy and impaired synthetic function (international normalized ratio $\geq 1.5$) in a subject free of preexistent chronic liver disease.

- **Acute pancreatitis**, defined as the American Gastroenterological Association (AGA) guidelines: the presence of two out of three of the following characteristics: a) abdominal pain consistent with the disease, b) serum amylase and/or lipase activity $>3$ times the upper limit of normal, and c) characteristic findings on abdominal imaging.

- **Thrombocytopenia**, defined as the platelet blood count $<50,000$ per µL.

- **Hypertransaminasemia**, defined as the elevation of alanine transaminase (ALT) and/or aspartate transaminase (AST) activity in serum, $>3$ times the upper normal limit of the laboratory reference.
As stated in the selection criteria, patients with the current use of anti-epileptics are allowed to be recruited, criteria that may include patients with epilepsy. In case of the need of other anti-epileptics to treat new or recurrent seizures, the inclusion of such medications will be a prerogative of the treating physician team. The investigational team of this trial will reinforce the maintenance of the patient in the study, by helping in the selection of anti-epileptics with no known adverse interactions with VPA, but in any particular case of perceived harm that may arise with the interaction of VPA with other anti-epileptics, the patient will be removed from the study.

**Study duration**

Ten days of i.v. treatment for the primary outcome, plus 30 days for the secondary outcome of COVID-19 recurrence, given a total of 40 days of follow-up.

**Major statistical hypothesis**

There will be at least a 50% reduction of death of patients with severe COVID-19 needing invasive mechanical ventilation (IMV).

**Sample size**

This is a proof-of-concept study, therefore, sample size calculation was performed by using the formula for the difference of proportions with a known (previous) proportion, and
assuming a high magnitude of the efficacy of the study drug, since, given the contingency of this pandemics, minor effect sizes reductions are not desirable.

According to the most extensive information available today on 1,591 Italian patients with severe COVID-19 admitted to ICU, it is expected a 40% CFR final disposition of patients, according to Bayesian analysis (the original information reports 26% CFR, but 58% of patients still in ICU as of the analysis deadline of March 25, 2020). Hence, the sample size was calculated to detect a minimum of (but not restricted to) 50% reduction in the CFR from 40% to 20%, with 80% study power and 5% type I error.

Therefore, a sample size of at least (but not restricted to) 43 patients will be needed to demonstrate an absolute (not RRR) reduction of 50% in CFR. No excess sample size was considered to cover study losses since ITT analysis requires that drop-outs are considered as failures to achieve study outcomes.

**Statistical plan**

ITT analyses will be performed considering all patients removed from the study for any reason as treatment failures. Per protocol (PP) analyses will also be performed considering in the calculations only patients with complete information and complete treatment schemes, but the analyses on the PP population will only be considered as hypothesis-generating to further pursue the study objectives with another robust design. Daily patient inspections will be performed in order to demonstrate first that valproic acid is not harmful, to review plasma levels (measured every 72 h), and clinical response. With this information, on a daily basis, statistical analyses will be performed for outcome differences by using chi-squared tests for categorical variables and hazard ratios to obtain effect sizes of study outcomes.
(primary and secondary outcomes), as well as safety outcomes. After completion of the study (either as per protocol or prematurely terminated), actuarial analyses with the Kaplan-Meier method will be performed for each study outcome to illustrate effect differences. All analyses performed will be two-tailed and considered significant when $p<0.05$.

**Interim analyses and termination rules**

This study will be terminated as per protocol when at least 43 patients complete 10 days of i.v. valproic acid therapy.

Premature termination will be executed when the following events occur:

- Since only a high effect size ($>50\%$) in reducing death will be considered worthwhile to pursue further clinical study on valproic acid activity on COVID-19, the outcome rate boundary to terminate prematurely this proof-of-concept study will be 10 deaths occurred in ventilated patients.

- A rate of acute side effects (either thrombocytopenia, acute liver disease or acute pancreatic injury) exceeding 4 cases (10\% event rate) will be considered unacceptable and will lead to premature termination, given that this rate exceeds the expected, given the current information on critically-ill patients exposed to valproic acid to treat epilepsy and status epilepticus.

**Conclusions**

It is necessary for a useful drug to treat COVID-19 and its consequences. Given that it is expected the duration of a long-lasting pandemic,\textsuperscript{25} it can be supposed that we will have
several ways to treat this disease, to improve several clinical outcomes of importance to
eventually stop the direct sanitary implications and the very high economic burden that the
COVID-19 pandemics has caused. Although long-term adverse effects and even pro-
inflammatory consequences have been reported with the chronic use of VPA, given the
urgent need for a drug active against COVID-19 to shorten the high mortality and LOS, the
study of VPA is justified from a scientific standpoint.

Acknowledgements

The authors are grateful to the authorities, colleagues, and patients of Instituto Nacional de
Ciencias Médicas y Nutrición Salvador Zubirán for their support to perform this trial, as well as
the grants of possible donors that are currently evaluating this investigation idea.

References

1. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for
   the treatment of epilepsy. CNS Drugs. 2002;16(10):669-94.
2. Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull.
   2003;37 Suppl 2:5-16.
3. Terbach N, Williams RS. Structure-function studies for the panacea, valproic acid.
   Biochem Soc Trans 2009; 37: 1126–32.
4. Amirzargar MA, Yaghubi F, Hosseinipanah M, Jafari M, Pourjafar M, Rezaeepoor M, et al.
   Anti-inflammatory Effects of Valproic Acid in a Rat Model of Renal Ischemia/Reperfusion
   Injury: Alteration in Cytokine Profile. Inflammation. 2017 Aug;40(4):1310-1318.
   doi:10.1007/s10753-017-0574-9.
5. Hoşgörler F, Keleş D, Tanriverdi-Akhisaroğlu S, İnanç Ş, Akhisaroğlu M, Cankurt Ü, et al.
Anti-inflammatory and Anti-apoptotic Effect of Valproic Acid and Doxycycline Independent from MMP Inhibition in Early Radiation Damage. Balkan Med J. 2016 Sep;33(5):488-495.

6. Delgado FG, Cárdenas P, Castellanos JE. Valproic Acid Downregulates Cytokine Expression in Human Macrophages Infected with Dengue Virus. Diseases. 2018 Jul 6;6(3). pii: E59. doi: 10.3390/diseases6030059.

7. Seet LF, Toh LZ, Finger SN, Chu SWL, Wong TT. Valproic acid exerts specific cellular and molecular anti-inflammatory effects in post-operative conjunctiva. J Mol Med (Berl). 2019 Jan;97(1):63-75. doi: 10.1007/s00109-018-1722-x.

8. Kasotakis G, Galvan MD, Osathanugrah P, Dharia N, Bufe L, Breed Z, et al. Timing of valproic acid in acute lung injury: prevention is the best therapy? J Surg Res. 2017 Dec;220:206-212. doi: 10.1016/j.jss.2017.06.088.

9. Soria-Castro R, Schcolnik-Cabrera A, Rodríguez-López G, Campillo-Navarro M, Puebla-Osorio N, Estrada-Parra S, et al. Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells. J Immunol Res. 2019 Mar 14;2019:9678098. doi: 10.1155/2019/9678098.

10. Steinborn B, Zarowski M, Winczwewska-Wiktor A, Wójcicka M, Młodzikowska-Albrecht J, et al. Concentration of IL-1β, IL-2, IL-6, TNFα in the blood serum in children with generalized epilepsy treated by valproate. Pharmacol Rep. 2014 Dec;66(6):972-5. doi: 10.1016/j.pharep.2014.06.005.

11. Sonmez FM, Serin HM, Alver A, Aliyazicioglu R, Cansu A, Can G, et al. Blood levels of cytokines in children with idiopathic partial and generalized epilepsy. Seizure. 2013 Sep;22(7):517-21. doi: 10.1016/j.seizure.2013.03.014.

12. Shah IS, Yatham LN, Yeh CB, Ravindran AV. Effect of valproate on plasma levels of interleukin-6 in healthy male humans. Int Clin Psychopharmacol. 2005 Nov;20(6):295-8.
13. Crespillo AJ, Praena B, Bello-Morales R, Lerma L, Vázquez-Calvo A, Martín-Acebes MA, et al. Inhibition of herpes virus infection in oligodendrocyte cultured cells by valproic acid. Virus Res. 2016 Mar 2;214:71-9. doi: 10.1016/j.virusres.2016.01.009.

14. Vázquez-Calvo A, Saiz JC, Sobrino F, Martín-Acebes MA. Inhibition of enveloped virus infection of cultured cells by valproic acid. J Virol. 2011 Feb;85(3):1267-74. doi: 10.1128/JVI.01717-10.

15. Vázquez-Calvo Á, Martín-Acebes MA, Sáiz JC, Ngo N, Sobrino F, de la Torre JC. Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid. Antiviral Res. 2013 Aug;99(2):172-9. doi: 10.1016/j.antiviral.2013.05.012.

16. Praena B, Bello-Morales R, de Castro F, López-Guerrero JA. Amidic derivatives of valproic acid, valpromide and valnoctamide, inhibit HSV-1 infection in oligodendrocytes. Antiviral Res. 2019 Aug;168:91-99. doi:10.1016/j.antiviral.2019.05.006.

17. Jin H, Guo X. Valproic acid ameliorates coxsackievirus-B3-induced viral myocarditis by modulating Th17/Treg imbalance. Virol J. 2016 Oct 10;13(1):168.

18. Chen S, Ye J, Chen X, Shi J, Wu W, Lin W, et al. Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-κB pathway dependent of HDAC3. J Neuroinflammation. 2018 May 18;15(1):150.doi:

19. Chen X, Wang H, Zhou M, Li X, Fang Z, Gao H, et al. Valproic Acid Attenuates Traumatic Brain Injury-Induced Inflammation in Vivo: Involvement of Autophagy and the Nrf2/ARE Signaling Pathway. Front Mol Neurosci. 2018 Apr 17;11:117. doi: 10.3389/fnmol.2018.00117.

20. Dambach H, Hinkerohe D, Prochnow N, Stienen MN, Moinfar Z, Haase CG, Hufnagel A, Faustmann PM. Glia and epilepsy: experimental investigation of antiepileptic drugs in an astroglia/microglia co-culture model of inflammation. Epilepsia. 2014 Jan;55(1):184-92. doi: 10.1111/epi.12473.
21. Noël Fa, Lima J. Pharmacological aspects and clues for the rational use of Chloroquine/Hydroxychloroquine facing the therapeutic challenges of COVID-19 pandemic. Lat Am J Clin Sci Med Technol. 2020 Apr; 2: 28-34.

22. Zuluaga AF, Rodriguez CA, Montoya-Giraldo MA. Which is the pharmacodynamic target to calculate a rational dose against SARS-Cov-2? Lat Am J Clin Sci Med Technol. 2020 Apr; 2: 35-37.

23. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology. 2018 Mar;154(4):1096-1101.

24. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6. doi: 10.1001/jama.2020.5394. [Epub ahead of print]

25. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020 Apr 14. pii: eabb5793. doi: 10.1126/science.abb5793.
Figure. Diagrammatic study outline: methods of an open-label proof-of-concept trial of intravenous valproic acid for severe COVID-19.
**VPA in severe COVID-19**

**a proof-of-concept trial**

Adults with COVID-19 needing IVM

Day 0

Day 3
(AVP plasma levels)

Day 6
(AVP plasma levels)

Day 9
(AVP plasma levels)

Day 10

**Follow-up**

Daily follow-up clinical examinations

Study initiation

Daily vigilance on safety:
- Acute liver failure
- Acute pancreatitis
- Thrombocytopenia

Study termination

**ITT analysis**

**Primary outcome:**
- Case fatality rate

**Secondary outcomes:**
- Length of stay
- COVID-19 recurrence at 30-day follow-up

* Since only a high effect size in reducing death will be considered worthwhile to pursue further clinical study on valproic acid activity on COVID-19, the outcome rate boundary to terminate prematurely this proof-of-concept study will be 10 deaths occurred in ventilated patients.
VPA in severe COVID-19
a proof-of-concept trial

Adults with COVID-19 needing IVM

Day 0
Day 3 (AVP plasma levels)
Day 6 (AVP plasma levels)
Day 9 (AVP plasma levels)
Day 10

Follow-up

Daily follow-up clinical examinations

Study initiation

Daily vigilance on safety:
- Acute liver failure
- Acute pancreatitis
- Thrombocytopenia

Study termination

* Since only a high effect size in reducing death will be considered worthwhile to pursue further clinical study on valproic acid activity on COVID-19, the outcome rate boundary to terminate prematurely this proof-of-concept study will be 10 deaths occurred in ventilated patients.

ITT analysis

Primary outcome:
- Case fatality rate

Secondary outcomes:
- Length of stay
- COVID-19 recurrence at 30-day follow-up